Dr. Apolo on Managing Toxicities of Checkpoint Inhibitors in Bladder Cancer

Andrea B. Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses managing immune-related toxicities from checkpoint inhibitors in patients with bladder cancer.

According to Apolo, there are guidelines in the management of immune-related toxicities. Since some toxicities are rare, not all physicians have much experience managing them, making the guidelines a useful tool for patients with bladder cancer.